NasdaqGS:SNDXBiotechs
How the Latest Pipeline News Impacts the Value Story for Syndax Pharmaceuticals in 2025
Wondering if Syndax Pharmaceuticals is a bargain or just treading water? You are not alone, as plenty of investors are seeking clarity on its current valuation story.
The stock has seen some notable ups and downs recently. It rose 1.3% over the last week but remains down 12.2% in the past month and nearly 28% over the last year, reflecting shifting market expectations around growth and risk.
Much of this volatility has been driven by news about pipeline developments, specifically updates on...